Prosecution Insights
Last updated: October 25, 2026

Rebel Medicine Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Rebel Medicine Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, leaving a single examination path for review.

SOROUSH, LAYLA is the busiest examiner, with 1 pending matter. The focused record supports a direct assessment of the action and a response tailored to the identified claim issues.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SOROUSH, LAYLA 1 40.5% +43.4%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18422543 PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN SOROUSH, LAYLA 84d

Top Art Units

Art UnitApps
1622 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18422543 PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN SOROUSH, LAYLA 1622 §103DP Final Rejection 84d Pending Jan 25, 2024

Managing Rebel Medicine Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Rebel Medicine Inc. have?

Rebel Medicine Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Rebel Medicine Inc. applications?

Layla Soroush has the most, with 1 of Rebel Medicine Inc.'s pending office actions.

What technology area are Rebel Medicine Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month